NCT00072748View on ClinicalTrials.gov

Study Evaluating EKB-569 in Advanced Colorectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

63

Participants

Timeline

Start Date

Not specified

Primary Completion Date

October 31, 2004

Study Completion Date

October 31, 2004

Conditions
Colorectal NeoplasmsColonic NeoplasmsRectal Neoplasms
Interventions
DRUG

EKB-569

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00072748 - Study Evaluating EKB-569 in Advanced Colorectal Cancer | Biotech Hunter | Biotech Hunter